Search This Blog

Sunday, December 9, 2018

Roth Capital Starts CorMedix (CRMD) at Buy


Roth Capital analyst Jerry Issacson initiates coverage on CorMedix (NYSE: CRMD) with a Buy rating

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)